300558 贝达药业
已收盘 07-29 15:00:00
资讯
新帖
简况
贝达药业(300558)7月26日主力资金净买入219.81万元
证券之星 · 07-29 09:22
贝达药业(300558)7月26日主力资金净买入219.81万元
贝达药业(300558)股东宁波凯铭投资管理合伙企业(有限合伙)质押5万股,占总股本0.01%
证券之星 · 07-25
贝达药业(300558)股东宁波凯铭投资管理合伙企业(有限合伙)质押5万股,占总股本0.01%
贝达药业:瑞普晨创是贝达梦工场生物医药众创空间的入驻企业,也是贝达创新生态圈的合作企业
证券之星 · 07-24
贝达药业:瑞普晨创是贝达梦工场生物医药众创空间的入驻企业,也是贝达创新生态圈的合作企业
贝达药业(300558.SZ)发预增,预计上半年净利润2.08亿元-2.37亿元,同比增长40%-60%
智通财经网 · 07-23
贝达药业(300558.SZ)发预增,预计上半年净利润2.08亿元-2.37亿元,同比增长40%-60%
贝达药业:预计2024年1-6月归属净利润盈利2.08亿元至2.37亿元
证券之星 · 07-23
贝达药业:预计2024年1-6月归属净利润盈利2.08亿元至2.37亿元
贝达药业最新公告:预计上半年净利同比增长40%-60%
证券之星 · 07-23
贝达药业最新公告:预计上半年净利同比增长40%-60%
贝达药业(300558)7月15日主力资金净卖出711.50万元
证券之星 · 07-16
贝达药业(300558)7月15日主力资金净卖出711.50万元
贝达药业最新公告:EYP-1901玻璃体内植入剂药物获得临床试验批准通知书
证券之星 · 07-15
贝达药业最新公告:EYP-1901玻璃体内植入剂药物获得临床试验批准通知书
贝达药业(300558.SZ):EYP-1901玻璃体内植入剂药物获得临床试验批准
智通财经 · 07-15
贝达药业(300558.SZ):EYP-1901玻璃体内植入剂药物获得临床试验批准
贝达药业:埃克替尼目前没有胃癌适应症相关的项目立项
证券之星 · 07-11
贝达药业:埃克替尼目前没有胃癌适应症相关的项目立项
贝达药业(300558)股东宁波凯铭投资管理合伙企业(有限合伙)质押85万股,占总股本0.21%
证券之星 · 07-08
贝达药业(300558)股东宁波凯铭投资管理合伙企业(有限合伙)质押85万股,占总股本0.21%
贝达药业:截至目前,公司与上海泽德曼医药未有项目合作
证券之星 · 07-05
贝达药业:截至目前,公司与上海泽德曼医药未有项目合作
贝达药业:目前股东质押总体风险处于可控水平,其所质押的股份不存在平仓风险或被强制过户风险
证券之星 · 07-03
贝达药业:目前股东质押总体风险处于可控水平,其所质押的股份不存在平仓风险或被强制过户风险
贝达药业(300558)股东宁波凯铭投资管理合伙企业(有限合伙)质押20万股,占总股本0.05%
证券之星 · 07-02
贝达药业(300558)股东宁波凯铭投资管理合伙企业(有限合伙)质押20万股,占总股本0.05%
贝达药业(300558)6月27日主力资金净买入790.20万元
证券之星 · 06-28
贝达药业(300558)6月27日主力资金净买入790.20万元
贝达药业(300558)6月25日主力资金净卖出414.29万元
证券之星 · 06-26
贝达药业(300558)6月25日主力资金净卖出414.29万元
贝达药业(300558)股东宁波凯铭投资管理合伙企业(有限合伙)质押20万股,占总股本0.05%
证券之星 · 06-24
贝达药业(300558)股东宁波凯铭投资管理合伙企业(有限合伙)质押20万股,占总股本0.05%
贝达药业(300558)股东宁波凯铭投资管理合伙企业(有限合伙)质押605.5万股,占总股本1.45%
证券之星 · 06-21
贝达药业(300558)股东宁波凯铭投资管理合伙企业(有限合伙)质押605.5万股,占总股本1.45%
贝达药业(300558)6月19日主力资金净卖出773.65万元
证券之星 · 06-20
贝达药业(300558)6月19日主力资金净卖出773.65万元
贝达药业公布国际专利申请:“一种靶向泛KRAS蛋白降解剂的化合物及其应用”
证券之星 · 06-16
贝达药业公布国际专利申请:“一种靶向泛KRAS蛋白降解剂的化合物及其应用”
暂无数据
公司概况
公司名称:
贝达药业股份有限公司
所属行业:
医药制造业
上市日期:
2016-11-07
主营业务:
贝达药业股份有限公司主营业务为创新药物的生产与销售。公司主要产品和服务有贝安汀、贝美纳、凯美纳、赛美纳、伏美纳。公司明星产品凯美纳获得了国家知识产权局和世界专利组织联合颁发的中国专利金奖(两次)、我国工业界“奥斯卡奖”、中国工业大奖、人民网和中国药促会联合颁发的最具临床价值创新药奖、入选新中国70年卫生健康大事记等。荣获2022浙江省药学会科学技术特等奖。
发行价格:
17.57
{"stockData":{"symbol":"300558","market":"SZ","secType":"STK","nameCN":"贝达药业","latestPrice":31.3,"timestamp":1722236622000,"preClose":32.04,"halted":0,"volume":7508294,"delay":0,"floatShares":417000000,"shares":418000000,"eps":0.9434,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.74,"latestTime":"07-29 15:00:00","open":32.37,"high":32.56,"low":31.24,"amount":238000000,"amplitude":0.0412,"askPrice":31.3,"askSize":45,"bidPrice":31.29,"bidSize":18,"shortable":0,"etf":0,"ttmEps":0.9434,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1722303000000},"adr":0,"adjPreClose":32.04,"symbolType":"stock","openAndCloseTimeList":[[1722216600000,1722223800000],[1722229200000,1722236400000]],"highLimit":35.24,"lowLimit":28.84,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":418485885,"pbRate":2.43,"roa":"--","roe":"1.82%","epsLYR":0.83,"committee":0.146919,"marketValue":13099000000,"floatMarketCap":13057000000,"peRate":33.177866,"changeRate":-0.0231,"turnoverRate":0.018,"status":1},"requestUrl":"/m/hq/s/300558/tweets","defaultTab":"tweets","newsList":[{"id":"2455776015","title":"贝达药业(300558)7月26日主力资金净买入219.81万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2455776015","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2455776015?lang=zh_cn&edition=full","pubTime":"2024-07-29 09:22","pubTimestamp":1722216170,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月26日收盘,贝达药业报收于32.04元,下跌0.77%,换手率2.12%,成交量8.82万手,成交额2.84亿元。近5日资金流向一览见下表:贝达药业融资融券信息显示,融资方面,当日融资买入3171.0万元,融资偿还1558.94万元,融资净买入1612.06万元。贝达药业主营业务:抗癌药物的生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072900002673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"gpt_icon":0},{"id":"2454626879","title":"贝达药业(300558)股东宁波凯铭投资管理合伙企业(有限合伙)质押5万股,占总股本0.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2454626879","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454626879?lang=zh_cn&edition=full","pubTime":"2024-07-25 21:29","pubTimestamp":1721914181,"startTime":"0","endTime":"0","summary":"证券之星消息,贝达药业7月25日公开信息显示,股东宁波凯铭投资管理合伙企业向浙商证券股份有限公司合计质押5.0万股,占总股本0.01%。质押详情见下表:截止本公告日,股东宁波凯铭投资管理合伙企业已累计质押股份5454.4万股,占其持股总数的68.13%。贝达药业主营业务:抗癌药物的生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072500045065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","BK0239"],"gpt_icon":0},{"id":"2453974075","title":"贝达药业:瑞普晨创是贝达梦工场生物医药众创空间的入驻企业,也是贝达创新生态圈的合作企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2453974075","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453974075?lang=zh_cn&edition=full","pubTime":"2024-07-24 17:05","pubTimestamp":1721811918,"startTime":"0","endTime":"0","summary":"瑞普晨创是贝达梦工场生物医药众创空间的入驻企业,也是贝达创新生态圈的合作企业。公司会关注瑞普晨创的发展动态,推动生态圈企业间协同、互动。在上市产品方面,公司目前有凯美纳、贝美纳、赛美纳、伏美纳、贝安汀5款上市药品,其中4款药品已纳入国家医保目录。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072400039205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","161726","BK0239","399441"],"gpt_icon":0},{"id":"2453003592","title":"贝达药业(300558.SZ)发预增,预计上半年净利润2.08亿元-2.37亿元,同比增长40%-60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453003592","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453003592?lang=zh_cn&edition=full","pubTime":"2024-07-23 20:01","pubTimestamp":1721736097,"startTime":"0","endTime":"0","summary":"智通财经APP讯,贝达药业 发布2024年半年度业绩预告,预计归属于上市公司股东的净利润2.08亿元–2.37亿元,同比增长40%-60%;扣除非经常性损益后的净利润2.12亿元–2.30亿元,同比增长140%-160%。报告期内,公司有盐酸埃克替尼片、盐酸恩沙替尼胶囊、贝伐珠单抗注射液、甲磺酸贝福替尼胶囊及伏罗尼布片5款上市药品,其中4款药品已纳入国家医保目录。同时,公司持续加强市场推广工作,积极推进药品在全国医院、药店的准入,提升药品市场份额。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1154636.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300558"],"gpt_icon":0},{"id":"2453203534","title":"贝达药业:预计2024年1-6月归属净利润盈利2.08亿元至2.37亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2453203534","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453203534?lang=zh_cn&edition=full","pubTime":"2024-07-23 20:00","pubTimestamp":1721736041,"startTime":"0","endTime":"0","summary":"证券之星消息,贝达药业发布业绩预告,预计2024年1-6月归属净利润盈利2.08亿元至2.37亿元。2024年半年度公司主营业务收入同比稳步增长,经营效率进一步提升,公司业绩相应实现稳定增长。贝达药业2024年一季报显示,公司主营收入7.36亿元,同比上升38.4%;归母净利润9814.07万元,同比上升90.95%;扣非净利润8956.28万元,同比上升390.39%;负债率39.82%,投资收益-215.2万元,财务费用994.75万元,毛利率82.53%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072300039038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558"],"gpt_icon":0},{"id":"2453366035","title":"贝达药业最新公告:预计上半年净利同比增长40%-60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453366035","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453366035?lang=zh_cn&edition=full","pubTime":"2024-07-23 20:00","pubTimestamp":1721736009,"startTime":"0","endTime":"0","summary":"贝达药业公告,预计上半年净利2.08亿元–2.37亿元,同比增长40%-60%。报告期内,公司有盐酸埃克替尼片、盐酸恩沙替尼胶囊、贝伐珠单抗注射液、甲磺酸贝福替尼胶囊及伏罗尼布片5款上市药品,其中4款药品已纳入国家医保目录。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072300039062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300558"],"gpt_icon":0},{"id":"2451860719","title":"贝达药业(300558)7月15日主力资金净卖出711.50万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451860719","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451860719?lang=zh_cn&edition=full","pubTime":"2024-07-16 09:15","pubTimestamp":1721092538,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月15日收盘,贝达药业报收于31.18元,下跌4.24%,换手率1.46%,成交量6.08万手,成交额1.91亿元。近5日资金流向一览见下表:贝达药业融资融券信息显示,融资方面,当日融资买入1761.85万元,融资偿还1609.61万元,融资净买入152.24万元,连续3日净买入累计1019.16万元。贝达药业主营业务:抗癌药物的生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071600014355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"gpt_icon":0},{"id":"2451613182","title":"贝达药业最新公告:EYP-1901玻璃体内植入剂药物获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2451613182","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451613182?lang=zh_cn&edition=full","pubTime":"2024-07-15 16:20","pubTimestamp":1721031646,"startTime":"0","endTime":"0","summary":"贝达药业公告,今日,贝达药业股份有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》,公司与EyePoint Pharmaceuticals, Inc.共同申报的EYP-1901玻璃体内植入剂湿性年龄相关性黄斑变性适应症药物临床试验申请已获得NMPA批准开展。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071500019792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03347","BK0060","300558","BK1576","BK0239","BK1141","BK1583"],"gpt_icon":0},{"id":"2451515690","title":"贝达药业(300558.SZ):EYP-1901玻璃体内植入剂药物获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2451515690","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451515690?lang=zh_cn&edition=full","pubTime":"2024-07-15 15:52","pubTimestamp":1721029974,"startTime":"0","endTime":"0","summary":"智通财经APP讯, 贝达药业 发布公告,公司收到国家药品监督管理局签发的《药物临床试验批准通知书》,公司与 EyePoint Pharmaceuticals, Inc.共同申报的EYP-1901玻璃体内植入剂湿性年龄相关性黄斑变性适应症药物临床试验申请已获得NMPA批准开展。据悉,EYP-1901玻璃体内植入剂通过EyePoint专有的可生物降解的缓释技术Durasert ETM将伏罗尼布注射进入玻璃体内,使伏罗尼布以可控且可耐受的方式持续地在眼部释放。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1150856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK1141","BK0060","300558","BK1583","03347","BK0239"],"gpt_icon":0},{"id":"2450336552","title":"贝达药业:埃克替尼目前没有胃癌适应症相关的项目立项","url":"https://stock-news.laohu8.com/highlight/detail?id=2450336552","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450336552?lang=zh_cn&edition=full","pubTime":"2024-07-11 17:04","pubTimestamp":1720688678,"startTime":"0","endTime":"0","summary":"证券之星消息,贝达药业07月11日在投资者关系平台上答复投资者关心的问题。埃克替尼目前没有胃癌适应症相关的项目立项。同时,公司股东如有增持股份计划,会按照相关法律法规的要求及时公开披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071100033744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300558"],"gpt_icon":0},{"id":"2449703627","title":"贝达药业(300558)股东宁波凯铭投资管理合伙企业(有限合伙)质押85万股,占总股本0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449703627","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449703627?lang=zh_cn&edition=full","pubTime":"2024-07-08 21:29","pubTimestamp":1720445374,"startTime":"0","endTime":"0","summary":"证券之星消息,贝达药业7月8日公开信息显示,股东宁波凯铭投资管理合伙企业向浙商证券股份有限公司、申万宏源证券有限公司、招商证券股份有限公司合计质押85.0万股,占总股本0.21%。质押详情见下表:截止本公告日,股东宁波凯铭投资管理合伙企业已累计质押股份5472.4万股,占其持股总数的68.35%。贝达药业主营业务:抗癌药物的生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070800032127.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"gpt_icon":0},{"id":"2449252713","title":"贝达药业:截至目前,公司与上海泽德曼医药未有项目合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2449252713","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449252713?lang=zh_cn&edition=full","pubTime":"2024-07-05 18:05","pubTimestamp":1720173924,"startTime":"0","endTime":"0","summary":"投资者:请问董秘,贝达药业是否有与泽德曼医药科技合作项目TAP-1503乳膏商业化权益计划?截至目前,公司与上海泽德曼医药未有项目合作。未来如有重大项目合作,公司会按照法规规定及时履行披露义务。贝达药业也拥有强大的市场销售团队,作为贝达药业四架马车的市场销售和创新生态圈,贝达药业有没有合作项目产品进行独家商业化运作?截至2024年6月28日,公司A股普通股股东总数为31,946户。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500037276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0060","159938","BK1161","09939","BK1515","BK1574","BK0239"],"gpt_icon":0},{"id":"2448177974","title":"贝达药业:目前股东质押总体风险处于可控水平,其所质押的股份不存在平仓风险或被强制过户风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2448177974","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448177974?lang=zh_cn&edition=full","pubTime":"2024-07-03 18:04","pubTimestamp":1720001071,"startTime":"0","endTime":"0","summary":"证券之星消息,贝达药业07月03日在投资者关系平台上答复投资者关心的问题。目前股东质押总体风险处于可控水平,其所质押的股份不存在平仓风险或被强制过户风险。公司董监高如有增持股份计划,会按照相关法律法规的要求及时公开披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070300037639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"gpt_icon":0},{"id":"2448151060","title":"贝达药业(300558)股东宁波凯铭投资管理合伙企业(有限合伙)质押20万股,占总股本0.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448151060","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448151060?lang=zh_cn&edition=full","pubTime":"2024-07-02 21:25","pubTimestamp":1719926740,"startTime":"0","endTime":"0","summary":"证券之星消息,贝达药业7月2日公开信息显示,股东宁波凯铭投资管理合伙企业向申万宏源证券有限公司合计质押20.0万股,占总股本0.05%。质押详情见下表:截止本公告日,股东宁波凯铭投资管理合伙企业已累计质押股份5387.4万股,占其持股总数的67.29%。贝达药业主营业务:抗癌药物的生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070200034669.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"gpt_icon":0},{"id":"2446519893","title":"贝达药业(300558)6月27日主力资金净买入790.20万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446519893","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446519893?lang=zh_cn&edition=full","pubTime":"2024-06-28 09:22","pubTimestamp":1719537765,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月27日收盘,贝达药业报收于33.0元,下跌3.93%,换手率0.99%,成交量4.12万手,成交额1.37亿元。近5日资金流向一览见下表:贝达药业融资融券信息显示,融资方面,当日融资买入1501.27万元,融资偿还823.74万元,融资净买入677.54万元。贝达药业主营业务:抗癌药物的生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062800015829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300558"],"gpt_icon":0},{"id":"2446280787","title":"贝达药业(300558)6月25日主力资金净卖出414.29万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446280787","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446280787?lang=zh_cn&edition=full","pubTime":"2024-06-26 09:23","pubTimestamp":1719364981,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月25日收盘,贝达药业报收于33.0元,下跌2.94%,换手率1.43%,成交量5.97万手,成交额1.99亿元。近5日资金流向一览见下表:贝达药业融资融券信息显示,融资方面,当日融资买入1851.65万元,融资偿还1840.71万元,融资净买入10.94万元。贝达药业主营业务:抗癌药物的生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600013868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"gpt_icon":0},{"id":"2445907414","title":"贝达药业(300558)股东宁波凯铭投资管理合伙企业(有限合伙)质押20万股,占总股本0.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2445907414","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445907414?lang=zh_cn&edition=full","pubTime":"2024-06-24 21:25","pubTimestamp":1719235544,"startTime":"0","endTime":"0","summary":"证券之星消息,贝达药业6月24日公开信息显示,股东宁波凯铭投资管理合伙企业向申万宏源证券有限公司合计质押20.0万股,占总股本0.05%。质押详情见下表:截止本公告日,股东宁波凯铭投资管理合伙企业已累计质押股份6018.86万股,占其持股总数的75.18%。贝达药业主营业务:抗癌药物的生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062400032575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","BK0239"],"gpt_icon":0},{"id":"2445757479","title":"贝达药业(300558)股东宁波凯铭投资管理合伙企业(有限合伙)质押605.5万股,占总股本1.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2445757479","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445757479?lang=zh_cn&edition=full","pubTime":"2024-06-21 21:25","pubTimestamp":1718976344,"startTime":"0","endTime":"0","summary":"证券之星消息,贝达药业6月21日公开信息显示,股东宁波凯铭投资管理合伙企业向国元证券股份有限公司合计质押605.5万股,占总股本1.45%。质押详情见下表:截止本公告日,股东宁波凯铭投资管理合伙企业已累计质押股份5998.86万股,占其持股总数的74.93%。贝达药业主营业务:抗癌药物的生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062100051032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300558"],"gpt_icon":0},{"id":"2444235356","title":"贝达药业(300558)6月19日主力资金净卖出773.65万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2444235356","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444235356?lang=zh_cn&edition=full","pubTime":"2024-06-20 09:23","pubTimestamp":1718846620,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月19日收盘,贝达药业报收于35.94元,下跌2.63%,换手率0.98%,成交量4.1万手,成交额1.49亿元。近5日资金流向一览见下表:贝达药业融资融券信息显示,融资方面,当日融资买入1704.68万元,融资偿还1451.57万元,融资净买入253.11万元。贝达药业主营业务:抗癌药物的生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062000013236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"gpt_icon":0},{"id":"2443990811","title":"贝达药业公布国际专利申请:“一种靶向泛KRAS蛋白降解剂的化合物及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2443990811","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443990811?lang=zh_cn&edition=full","pubTime":"2024-06-16 04:33","pubTimestamp":1718483600,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示贝达药业公布了一项国际专利申请,专利名为“一种靶向泛KRAS蛋白降解剂的化合物及其应用”,专利申请号为PCT/CN2023/136686,国际公布日为2024年6月13日。专利详情如下:图片来源:世界知识产权组织今年以来贝达药业已公布的国际专利申请5个,较去年同期减少了28.57%。结合公司2023年年报财务数据,2023年公司在研发方面投入了6.4亿元,同比减8.54%。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061600000296.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2016-11-07","address":"浙江省杭州市临平区经济技术开发区兴中路355号","stockEarnings":[{"period":"1week","weight":-0.0222},{"period":"1month","weight":-0.0384},{"period":"3month","weight":-0.2466},{"period":"6month","weight":-0.17},{"period":"1year","weight":-0.4491},{"period":"ytd","weight":-0.3901}],"companyName":"贝达药业股份有限公司","boardCode":"AI0027","perCapita":"13058股","boardName":"医药制造业","registeredCapital":"41848万元","compareEarnings":[{"period":"1week","weight":-0.0244},{"period":"1month","weight":-0.0255},{"period":"3month","weight":-0.0686},{"period":"6month","weight":0.037},{"period":"1year","weight":-0.1172},{"period":"ytd","weight":-0.0279}],"survey":" 贝达药业股份有限公司主营业务为创新药物的生产与销售。公司主要产品和服务有贝安汀、贝美纳、凯美纳、赛美纳、伏美纳。公司明星产品凯美纳获得了国家知识产权局和世界专利组织联合颁发的中国专利金奖(两次)、我国工业界“奥斯卡奖”、中国工业大奖、人民网和中国药促会联合颁发的最具临床价值创新药奖、入选新中国70年卫生健康大事记等。荣获2022浙江省药学会科学技术特等奖。","serverTime":1722295338339,"listedPrice":17.57,"stockholders":"31946人(较上一季度减少0.27%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"贝达药业,300558,贝达药业股票,贝达药业股票老虎,贝达药业股票老虎国际,贝达药业行情,贝达药业股票行情,贝达药业股价,贝达药业股市,贝达药业股票价格,贝达药业股票交易,贝达药业股票购买,贝达药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}